India set to approve Biocad's biosimilar rituximab

Biocad CJSC (Saint Petersburg, Russia) said India’s Central Drugs Standard Control Organization (CDSCO) recommended approval of AcellBia (BCD-020), a biosimilar of rituximab. Biocad expects the product be approved next month, with a launch planned for September...